<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04773028</url>
  </required_header>
  <id_info>
    <org_study_id>2020-071</org_study_id>
    <nct_id>NCT04773028</nct_id>
  </id_info>
  <brief_title>The Role of Matrix Metalloproteinase 2 and 9 Enzymes in Developing Chronic Thromboembolic Pulmonary Hypertension</brief_title>
  <official_title>The Role of Matrix Metalloproteinase 2 and 9 Enzymes in Developing Chronic Thromboembolic Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHMET ZENGIN</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kartal Kosuyolu High Speciality Training and Research Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic thromboembolic pulmonary hypertension is an occlusive disease in pulmonary&#xD;
      artery.Matrix metalloproteinase enzymes play a substantial role of extracellular matrix&#xD;
      remodeling. The clot formed in chronic thromboembolic pulmonary hypertension does not melt&#xD;
      and turns into a fibrous state, it occludes the pulmonary artery.In this study, investigators&#xD;
      aimed to investigate the role of matrix metalloproteinase enzymes in pulmonary arterial wall&#xD;
      remodeling in patients with chronic thromboembolic pulmonary hypertension&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic thromboembolic pulmonary hypertension is an occlusive disease in pulmonary artery.&#xD;
      Only 4% of patients with acute pulmonary embolism develop chronic thromboembolic pulmonary&#xD;
      hypertension and acute pulmonary embolism or deep vein thrombosis is reported in the&#xD;
      anamnesis of 75% of those with chronic thromboembolic disease. Therefore, the etiology of the&#xD;
      disease is not clear. Altought many studies are done, especially the role of inflamation is&#xD;
      emhasised underlie the disease.&#xD;
&#xD;
      Matrix metalloproteinase enzymes play a substantial role of extracellular matrix remodeling.&#xD;
      The clot formed in chronic thromboembolic pulmonary hypertension does not melt and turns into&#xD;
      a fibrous state, it occludes the pulmonary artery.In this study, investigators aimed to&#xD;
      investigate the role of matrix metalloproteinase enzymes in pulmonary arterial wall&#xD;
      remodeling in patients with chronic thromboembolic pulmonary hypertension.&#xD;
&#xD;
      Matrix metalloprotinase enzymes are known to play a role in atherosclerosis. This research&#xD;
      will investigate whether there is atherosclerosis together with inflamattion in the&#xD;
      background of chronic thromboembolic hypertension.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Actual">May 4, 2021</completion_date>
  <primary_completion_date type="Actual">May 4, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of Matrix Metalloproteinase 2 and 9 Enzymes</measure>
    <time_frame>1 year</time_frame>
    <description>Measurement the concentration of matrix metalloproteinase 2 and 9 enzymes by elisa and western blot techniques.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">48</enrollment>
  <condition>Chronic Thromboembolic Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>PATİENT GROUP(GROUP 1)</arm_group_label>
    <description>This group is the group that underwent pulmonary thromboendarterectomy due to chronic thromboembolic pulmonary hypertension.Sample was taken from the material extracted from this group during operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL GROUP(GROUP 2)</arm_group_label>
    <description>This group is the group that underwent lobectomy or pneumonectomy for another reason that the pulmonary artery is not affected. Patients operated for a reason other than chronic thromboembolic pulmonary hypertension and samples were taken from the intact pulmonary artery of the removed lung.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>matrix metalloproteinase enzymes 2 and 9</intervention_name>
    <description>concentration of matrix metalloproteinase 2 and 9 enzymes</description>
    <arm_group_label>CONTROL GROUP(GROUP 2)</arm_group_label>
    <arm_group_label>PATİENT GROUP(GROUP 1)</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples was teken from pulmonary endarterectomy material during the operation. This material&#xD;
      is removed routinly this surgical procedure. At this studt any extra surgical procedure did&#xD;
      not performed to participans.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study population has chronic thromboembolic pulmonary hypertension and will be performed&#xD;
        pulmonary thromboendarterectomy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Despite 3 months of anticoagulation therapy&#xD;
&#xD;
          -  mean pulmonary arterial pressure &gt; 20 mmHg&#xD;
&#xD;
          -  pulmonary vasculary resistance &gt; 3 wood&#xD;
&#xD;
          -  pulmonary capillary wedge pressure &lt; 15 mmHg&#xD;
&#xD;
          -  perfusion defect in ventilation perfusion scintigraphy&#xD;
&#xD;
          -  pulmonary angiography or computed tomography angiography showing pulmonary artery&#xD;
             occlusive lesions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing pulmonary thromboendarterectomy concomitant coronary bypass,&#xD;
             carotid endarterectomy, aortic valve, ascending aorta, mitral valve, tricuspid valve,&#xD;
             pulmonary valve surgery&#xD;
&#xD;
          -  Patients who have undergone surgical or percutaneous procedures due to atherosclerotic&#xD;
             disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>mehmet yanartas</last_name>
    <role>Study Director</role>
    <affiliation>kartal kosuyolu hıgh specıalty training and research hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kartal Kosuyolu High Speciality Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <state>Eyalet/Yerleşke</state>
        <zip>34800</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <results_first_submitted>May 4, 2021</results_first_submitted>
  <results_first_submitted_qc>August 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 10, 2021</results_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kartal Kosuyolu High Speciality Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>AHMET ZENGIN</investigator_full_name>
    <investigator_title>medical doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data used in the study will be kept closed to the use of other users.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 3, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT04773028/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 3, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT04773028/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PATİENT GROUP(GROUP 1)</title>
          <description>This group is the group that underwent pulmonary thromboendarterectomy due to chronic thromboembolic pulmonary hypertension.Sample was taken from the material extracted from this group during operation.&#xD;
matrix metalloproteinase enzymes 2 and 9: concentration of matrix metalloproteinase 2 and 9 enzymes</description>
        </group>
        <group group_id="P2">
          <title>CONTROL GROUP(GROUP 2)</title>
          <description>This group is the group that underwent lobectomy or pneumonectomy for another reason that the pulmonary artery is not affected. Patients operated for a reason other than chronic thromboembolic pulmonary hypertension and samples were taken from the intact pulmonary artery of the removed lung.&#xD;
matrix metalloproteinase enzymes 2 and 9: concentration of matrix metalloproteinase 2 and 9 enzymes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PATİENT GROUP(GROUP 1)</title>
          <description>This group is the group that underwent pulmonary thromboendarterectomy due to chronic thromboembolic pulmonary hypertension.Sample was taken from the material extracted from this group during operation.&#xD;
matrix metalloproteinase enzymes 2 and 9: concentration of matrix metalloproteinase 2 and 9 enzymes</description>
        </group>
        <group group_id="B2">
          <title>CONTROL GROUP(GROUP 2)</title>
          <description>This group is the group that underwent lobectomy or pneumonectomy for another reason that the pulmonary artery is not affected. Patients operated for a reason other than chronic thromboembolic pulmonary hypertension and samples were taken from the intact pulmonary artery of the removed lung.&#xD;
matrix metalloproteinase enzymes 2 and 9: concentration of matrix metalloproteinase 2 and 9 enzymes</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.04" spread="10.8"/>
                    <measurement group_id="B2" value="57.8" spread="15.4"/>
                    <measurement group_id="B3" value="53.42" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.6" spread="10.2"/>
                    <measurement group_id="B2" value="166.7" spread="7.6"/>
                    <measurement group_id="B3" value="166.65" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.4" spread="14.2"/>
                    <measurement group_id="B2" value="73.5" spread="13.9"/>
                    <measurement group_id="B3" value="79.45" spread="14.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Concentration of Matrix Metalloproteinase 2 and 9 Enzymes</title>
        <description>Measurement the concentration of matrix metalloproteinase 2 and 9 enzymes by elisa and western blot techniques.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATİENT GROUP(GROUP 1)</title>
            <description>This group is the group that underwent pulmonary thromboendarterectomy due to chronic thromboembolic pulmonary hypertension.Sample was taken from the material extracted from this group during operation.&#xD;
matrix metalloproteinase enzymes 2 and 9: concentration of matrix metalloproteinase 2 and 9 enzymes</description>
          </group>
          <group group_id="O2">
            <title>CONTROL GROUP(GROUP 2)</title>
            <description>This group is the group that underwent lobectomy or pneumonectomy for another reason that the pulmonary artery is not affected. Patients operated for a reason other than chronic thromboembolic pulmonary hypertension and samples were taken from the intact pulmonary artery of the removed lung.&#xD;
matrix metalloproteinase enzymes 2 and 9: concentration of matrix metalloproteinase 2 and 9 enzymes</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Matrix Metalloproteinase 2 and 9 Enzymes</title>
          <description>Measurement the concentration of matrix metalloproteinase 2 and 9 enzymes by elisa and western blot techniques.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PRO MMP 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89289.89" spread="84639.26"/>
                    <measurement group_id="O2" value="86548.72" spread="45312.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTİVE MMP 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205707.83" spread="388888.77"/>
                    <measurement group_id="O2" value="152911.57" spread="44400.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMP 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88975.83" spread="94129.68"/>
                    <measurement group_id="O2" value="182029.76" spread="140527.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-93054</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were not monitored/assessed</time_frame>
      <desc>Adverse Events were not monitored/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>PATİENT GROUP(GROUP 1)</title>
          <description>This group is the group that underwent pulmonary thromboendarterectomy due to chronic thromboembolic pulmonary hypertension.Sample was taken from the material extracted from this group during operation.&#xD;
matrix metalloproteinase enzymes 2 and 9: concentration of matrix metalloproteinase 2 and 9 enzymes</description>
        </group>
        <group group_id="E2">
          <title>CONTROL GROUP(GROUP 2)</title>
          <description>This group is the group that underwent lobectomy or pneumonectomy for another reason that the pulmonary artery is not affected. Patients operated for a reason other than chronic thromboembolic pulmonary hypertension and samples were taken from the intact pulmonary artery of the removed lung.&#xD;
matrix metalloproteinase enzymes 2 and 9: concentration of matrix metalloproteinase 2 and 9 enzymes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Ahmet Zengin</name_or_title>
      <organization>Kartal Kosuyolu Hihg Speciality Training and Research Hospital</organization>
      <phone>+905365022173</phone>
      <email>dr.zenginahmet@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

